Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Starts China Trial of PI3Kδ Inhibitor for Indolent Lymphoma

publication date: Apr 28, 2020

Suzhou Innovent Bio, has dosed the first patient in a pivotal China Phase II registrational trial of parsaclisib, a novel and selective PI3Kδ inhibitor. The trial is aimed at testing the efficacy and safety of parsaclisib in patients with indolent lymphoma -- either recurrent/refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL). In 2018, Innovent acquired greater China rights from Incyte for three clinical-stage candidates, including parsaclisib. Incyte is already testing parsaclisib in several non-Hodgkin lymphomas and in myelofibrosis, diffuse large B-cell lymphoma and autoimmune hemolytic anemia. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.